Literature DB >> 12965873

Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects.

Michael F Nielsen1, Andrea Caumo, Visvanathan Chandramouli, William C Schumann, Claudio Cobelli, Bernard R Landau, Hendrik Vilstrup, Robert A Rizza, Ole Schmitz.   

Abstract

Excess cortisol has been demonstrated to impair hepatic and extrahepatic insulin action. To determine whether glucose effectiveness and, in terms of endogenous glucose release (EGR), gluconeogenesis, also are altered by hypercortisolemia, eight healthy subjects were studied after overnight infusion with hydrocortisone or saline. Glucose effectiveness was assessed by a combined somatostatin and insulin infusion protocol to maintain insulin concentration at basal level in the presence of prandial glucose infusions. Despite elevated insulin concentrations (P < 0.05), hypercortisolemia resulted in higher glucose (P < 0.05) and free fatty acid concentrations (P < 0.05). Furthermore, basal insulin concentrations were higher during hydrocortisone than during saline infusion (P < 0.01), indicating the presence of steroid-induced insulin resistance. Postabsorptive glucose production (P = 0.64) and the fractional contribution of gluconeogenesis to EGR (P = 0.33) did not differ on the two study days. During the prandial glucose infusion, the integrated glycemic response above baseline was higher in the presence of hydrocortisone than during saline infusion (P < 0.05), implying a decrease in net glucose effectiveness (4.42 +/- 0.52 vs. 6.65 +/- 0.83 ml.kg-1.min-1; P < 0.05). To determine whether this defect is attributable to an impaired ability of glucose to suppress glucose production, to stimulate its own uptake, or both, glucose turnover and "hot" (labeled) indexes of glucose effectiveness (GE) were calculated. Hepatic GE was lower during cortisol than during saline infusion (2.39 +/- 0.24 vs. 3.82 +/- 0.51 ml.kg-1.min-1; P < 0.05), indicating a defect in the ability of glucose to restrain its own production. In addition, in the presence of excess cortisol, glucose disappearance was inappropriate for the prevailing glucose concentration, implying a decrease in glucose clearance (P < 0.05). The decrease in glucose clearance was confirmed by the higher increment in [3-3H]glucose during hydrocortisone than during saline infusion (P < 0.05), despite the administration of identical tracer infusion rates. In conclusion, short-term hypercortisolemia in healthy individuals with normal beta-cell function decreases insulin action but does not alter rates of EGR and gluconeogenesis. In addition, cortisol impairs the ability of glucose to suppress its own production, which due to accumulation of glucose in the glucose space results in impaired peripheral glucose clearance. These results suggest that cortisol excess impairs glucose tolerance by decreasing both insulin action and glucose effectiveness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965873     DOI: 10.1152/ajpendo.00566.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

1.  Insulin requirements in non-critically ill hospitalized patients with diabetes and steroid-induced hyperglycemia.

Authors:  Elias K Spanakis; Nina Shah; Keya Malhotra; Terri Kemmerer; Hsin-Chieh Yeh; Sherita Hill Golden
Journal:  Hosp Pract (1995)       Date:  2014-04

Review 2.  Glucose metabolism in Cushing's syndrome.

Authors:  Anu Sharma; Adrian Vella
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

3.  Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Rita Basu; Christopher J Ramnanan; Tiffany D Farmer; Doss Neal; Melanie Scott; Peer Jacobson; Robert A Rizza; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-16       Impact factor: 4.310

4.  Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease.

Authors:  Mayank Ajmera; Chan Shen; Usha Sambamoorthi
Journal:  Popul Health Manag       Date:  2016-09-30       Impact factor: 2.459

Review 5.  [Correlation of depression with stroke. Pathophysiological mechanisms].

Authors:  P Neu
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

6.  Twenty-eight-day bed rest with hypercortisolemia induces peripheral insulin resistance and increases intramuscular triglycerides.

Authors:  Melanie G Cree; Douglas Paddon-Jones; Bradley R Newcomer; Ola Ronsen; Asle Aarsland; Robert R Wolfe; Arny Ferrando
Journal:  Metabolism       Date:  2009-11-17       Impact factor: 8.694

7.  The metabolic changes caused by dexamethasone in the adjuvant-induced arthritic rat.

Authors:  Silvana M Caparroz-Assef; Ciomar A Bersani-Amado; Ana M Kelmer-Bracht; Adelar Bracht; Emy L Ishii-Iwamoto
Journal:  Mol Cell Biochem       Date:  2007-03-09       Impact factor: 3.396

8.  Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals.

Authors:  Sriram Gubbi; Ranganath Muniyappa; Susmeeta T Sharma; Shivraj Grewal; Raven McGlotten; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

9.  Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index.

Authors:  Marie-José C van Lierop; Wynand Alkema; Anke J Laskewitz; Rein Dijkema; Hans M van der Maaden; Martin J Smit; Ralf Plate; Paolo G M Conti; Christan G J M Jans; C Marco Timmers; Constant A A van Boeckel; Scott J Lusher; Ross McGuire; Rene C van Schaik; Jacob de Vlieg; Ruben L Smeets; Claudia L Hofstra; Annemieke M H Boots; Marcel van Duin; Benno A Ingelse; Willem G E J Schoonen; Aldo Grefhorst; Theo H van Dijk; Folkert Kuipers; Wim H A Dokter
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

10.  Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

Authors:  J Michael Gaziano; Anthony H Cincotta; Aaron Vinik; Lawrence Blonde; Nancy Bohannon; Richard Scranton
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.